The company will continue to push the drug in emerging markets like China, where the company sees opportunities for multibillion dollar sales.
Indeed. Thanks to sales in emerging markets, Lipitor will continue to be a big-selling drug even though it is now off-patent nearly everywhere. My best guess is that Lipitor continues to sell $3B+ worldwide for years to come, which is a pretty big deal even for a company as big as PFE.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”